Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amantadine extended release - Adamas Pharmaceuticals

Next Previous
Drug Profile

Amantadine extended release - Adamas Pharmaceuticals

Alternative Names: ADS-5101; ADS-5102; Amantadine controlled release; Amantadine ER; Amantadine HCl; Amantadine HCl extended release; GOCOVRI; GOCOVRI extended release; Nurelin

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Adamantanes; Antiparkinsonians; Antivirals; Organic bridged compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Discontinued Brain injuries; Movement disorders

Most Recent Events

  • 18 Mar 2024 Adamas Pharmaceuticals has patent pending for Amantadine extended release in world
  • 18 Mar 2024 Adamas Pharmaceuticals has patent protection for Amantadine extended release in USA and rest of world
  • 02 Apr 2022 Pooled efficacy and safety results from phase III trials in Drug-induced dyskinesia presented at the 74th Annual Meeting of the American Academy of Neurology (AAN-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top